Daily Cardiology Research Analysis
Analyzed 71 papers and selected 3 impactful papers.
Summary
A phase 3 randomized trial showed that the aldosterone synthase inhibitor baxdrostat produced a large, clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in resistant hypertension. A mechanistic Nature Communications study identified an IL-33–ST2–osteopontin axis between perivascular mesenchymal cells and reparative macrophages driving neointimal hyperplasia, mitigated by local siRNA hydrogel therapy. A prospective cohort analysis from MESA demonstrated that obstructive sleep apnea with high hypoxic burden or heightened heart rate response predicts incident atrial fibrillation.
Research Themes
- Resistant hypertension therapy via aldosterone synthase inhibition
- Immune–stromal crosstalk driving neointimal hyperplasia and anti-restenosis strategies
- Sleep apnea pathophysiology metrics predicting atrial fibrillation risk
Selected Articles
1. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
In a multicenter phase 3 RCT of resistant hypertension, baxdrostat reduced 24-hour ambulatory SBP by 16.6 mm Hg versus 2.6 mm Hg with placebo, yielding a placebo-corrected difference of −14.0 mm Hg at 12 weeks. Safety was acceptable with a small incidence of hyperkalemia >6 mmol/L (3%).
Impact: This is a rigorously conducted phase 3, double-blind RCT demonstrating substantial ambulatory BP reduction with a first-in-class aldosterone synthase inhibitor in resistant hypertension.
Clinical Implications: Baxdrostat may become an add-on option for resistant hypertension with robust ambulatory BP lowering; clinicians should monitor serum potassium and consider patient selection pending longer-term outcomes.
Key Findings
- Placebo-corrected reduction in 24-hour ambulatory SBP was −14.0 mm Hg (95% CI −17.2 to −10.8; p<0.0001) at 12 weeks.
- Least-squares mean change: −16.6 mm Hg (baxdrostat, n=89) vs −2.6 mm Hg (placebo, n=95).
- Adverse events occurred in 52% with baxdrostat vs 37% with placebo; confirmed hyperkalemia >6 mmol/L occurred in 3% vs 0%.
Methodological Strengths
- International, multicenter, randomized, double-blind, placebo-controlled phase 3 design with prespecified primary endpoint.
- Use of 24-hour ambulatory SBP and stratified randomization by baseline ambulatory SBP.
Limitations
- Relatively small randomized sample (n=217) after substantial exclusions during run-in.
- Short treatment duration (12 weeks) without long-term cardiovascular outcome data; modest increase in hyperkalemia risk.
Future Directions: Evaluate long-term efficacy and safety, cardiovascular outcomes, and comparative effectiveness versus mineralocorticoid receptor antagonists; define optimal monitoring protocols and subgroups.
BACKGROUND: Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension. METHODS: The Bax24 international, phase 3, randomised, double-blind, placebo-controlled trial recruited adults (aged ≥18 years) with seated systolic blood pressure (SBP) ≥140 mm Hg and <170 mm Hg, despite receiving three or more antihypertensive medications, including a diuretic, from 79 clinical sites (primary, secondary, and tertiary centres, in addition to research centres) in 22 countries. Following a 2-week placebo run-in period, patients with 24 h ambulatory SBP ≥130 mm Hg were randomly assigned (1:1) to receive 2 mg baxdrostat or placebo orally once daily for 12 weeks, in addition to background therapy (stratified by baseline ambulatory SBP <140 mm Hg or ≥140 mm Hg). Investigators, patients, and trial staff were masked to treatment assignment. The primary endpoint was change in 24 h ambulatory SBP from baseline to week 12, assessed by analysis of covariance in patients administered at least one dose of study medication with valid ambulatory SBP measurement at baseline and week 12. Missing or invalid ambulatory SBP measurements were not imputed. The safety analysis included all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT06168409, and is complete. FINDINGS: Between March 1, 2024, and April 16, 2025, 854 patients were screened, 636 were excluded (437 before the placebo run-in and 199 during the placebo run-in) and 217 were randomly assigned to and received baxdrostat (n=108) or placebo (n=109). 140 patients (65%) were male, 77 (35%) patients were female, and 170 patients (78%) were White. The median age was 60·0 years (IQR 51·0-68·0). At 12 weeks, the change from baseline in the least-squares mean 24 h ambulatory SBP was -16·6 mm Hg (95% CI -18·8 to -14·3) in the baxdrostat group (n=89) and -2·6 mm Hg (-4·7 to -0·4) in the placebo group (n=95); the estimated placebo-corrected difference was -14·0 mm Hg (-17·2 to -10·8; p<0·0001). Adverse events occurred in 56 (52%) of 108 patients in the baxdrostat group and 40 (37%) of 109 patients in the placebo group. A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients. INTERPRETATION: Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension. FUNDING: AstraZeneca.
2. Perivascular mesenchymal cells instruct ST2+ reparative macrophages to promote endovascular injury-induced neointimal hyperplasia in mice.
Perivascular MSCs produce IL-33 after injury, driving ST2+ macrophages to secrete osteopontin that promotes VSMC proliferation and neointimal hyperplasia. Local hydrogel delivery of siRNAs against Il33 or Spp1 attenuated neointimal growth, highlighting a tractable immuno-stromal axis to prevent restenosis.
Impact: Defines a previously underappreciated IL-33–ST2–OPN signaling axis linking stromal and immune compartments in vascular repair, with a feasible local RNAi therapeutic approach.
Clinical Implications: Targeting IL-33/ST2/OPN signaling or using local siRNA delivery platforms could complement endovascular procedures to reduce neointimal hyperplasia and restenosis risk.
Key Findings
- Injury-induced, NFκB-dependent IL-33 production by perivascular MSCs drives recruitment and phenotypic switching of ST2+ reparative macrophages.
- ST2+ macrophages produce osteopontin (SPP1), stimulating VSMC proliferation and neointimal formation.
- Local hydrogel-mediated siRNA delivery targeting Il33 or Spp1 effectively reduced injury-induced neointimal hyperplasia in mice.
Methodological Strengths
- Time-resolved single-cell transcriptomics to map immune–stromal dynamics.
- In vivo functional validation using local hydrogel-mediated siRNA knockdown of Il33/Spp1.
Limitations
- Preclinical mouse model (male mice) without human validation.
- Long-term safety and delivery scalability of local RNAi therapy are untested.
Future Directions: Translate findings into large-animal and early-phase human studies; explore stent-coating or periprocedural delivery of IL-33/OPN inhibitors; assess sex differences and chronic remodeling.
Tissue-resident mesenchymal stromal cells (MSC) instruct immune cell activation at injury sites, a key event in tissue repair. However, the full array of immunomodulatory mechanisms driving injury-responsive immune-stromal cell interactions is underexplored. Here, using an endovascular injury mouse model, we demonstrate that perivascular MSCs enhance arterial immune response by facilitating recruitment of ST2-expressing reparative macrophages in male mice. Time-resolved single-cell sequencing reveals an MSC-mediated, macrophage phenotypic switch, essential for vascular regeneration. Mechanistically, injury activates NFκB-dependent IL-33 production in MSCs, which acts as a paracrine signal that drives Osteopontin (OPN/SPP1) production in ST2+ macrophages and stimulates vascular smooth muscle cell (VSMC) proliferation and neointima formation. Local hydrogel-mediated delivery of siRNAs targeting Il33 or Spp1 effectively alleviates injury-induced neointimal hyperplasia, suggesting a potential therapeutic strategy to prevent restenosis and other vascular diseases. Our findings define an IL33-ST2-OPN axis that mediates functional crosstalk between perivascular MSCs and reparative macrophages, orchestrating immune-mediated reparative responses.
3. Association of High Cardiovascular Disease Risk Obstructive Sleep Apnea with Incident Atrial Fibrillation: the Multi-Ethnic Study of Atherosclerosis.
In 1,679 MESA participants, OSA characterized by high hypoxic burden or high heart rate response to respiratory events had a significantly higher risk of incident AF (HR 1.68) versus non-OSA, whereas low-risk OSA did not. Associations were similar in women and men.
Impact: Introduces physiologically enriched OSA metrics (hypoxic burden and heart rate surge) to refine AF risk prediction beyond AHI, informing targeted surveillance and prevention.
Clinical Implications: Patients with High-CVD-Risk OSA may benefit from closer AF surveillance and aggressive risk factor control; integrating hypoxic burden and ΔHR into sleep reports could guide cardiology referrals.
Key Findings
- High-CVD-Risk OSA (top tertile of hypoxic burden or ΔHR within AHI≥15) increased incident AF risk versus Non-OSA (HR 1.68; 95% CI 1.17–2.41).
- Low-CVD-Risk OSA (AHI≥15 without high HB/ΔHR) did not significantly increase AF risk (HR 1.20; 95% CI 0.76–1.92).
- Associations were consistent across sexes (women HR 1.71; men HR 1.64).
Methodological Strengths
- Prospective cohort with adjudicated AF and physiologic OSA metrics (hypoxic burden and heart rate response).
- Adjusted Cox models with consistent effects across sexes.
Limitations
- Observational design limits causal inference and residual confounding is possible.
- OSA stratification based on tertiles may vary across populations; no interventional test of OSA treatment was performed.
Future Directions: Test whether treating high hypoxic burden or blunted ΔHR modifies AF incidence; integrate metrics into clinical sleep reports and cardiology care pathways.
BACKGROUND: Obstructive sleep apnea (OSA) is associated with atrial fibrillation (AF), but this association varies by population and definitions of OSA and AF. RESEARCH QUESTION: Whether 'high cardiovascular disease risk' (High-CVD-Risk) OSA, defined by elevated hypoxic burden (HB) or heart rate response to respiratory events (ΔHR), is associated with incident AF. STUDY DESIGN AND METHODS: Using data from the Multi-Ethnic Study of Atherosclerosis, HB was quantified as the cumulative area under the desaturation curve following respiratory events, and ΔHR as the increase in heart rate upon event termination. Within OSA (apnea-hypopnea index (AHI) ≥15 events/h), High-CVD-Risk OSA was defined as having either a high ΔHR or high HB (both in highest tertile), while individuals with OSA who did not meet these criteria were considered as Low-CVD-Risk. Cox proportional hazards models were used to estimate the adjusted hazard ratios (HR) of incident AF for High- and Low-CVD-Risk OSA (vs Non-OSA, defined as an AHI < 15 events/h) after adjusting for confounders. RESULTS: A total of 1,679 participants (45.4% male) were included, with a median [interquartile range] age of 66.0 [60.0-74.0] years, HB of 35.3 [18.0-69.2] %min/h, and ΔHR of 7.7 [5.9-9.9] bpm. During a median follow-up of 6.7 years, AF was identified in 14.1% of the High-CVD-Risk OSA (n = 687), 10.1% of the Low-CVD-Risk OSA (n = 278), and 8.4% of the Non-OSA (n = 714). Compared to the Non-OSA, an increased hazard ratio for AF was found in High-CVD-Risk OSA (HR, 1.68; 95% CI,1.17-2.41) but not in Low-CVD-Risk OSA (HR, 1.20; 95% CI, 0.76-1.92). The adjusted hazard ratio was similar in women and men ([HR, 1.71; 95% CI, 1.01-2.91] vs [HR, 1.64; 95% CI, 0.99-2.72]). INTERPRETATION: OSA-related hypoxemia or heart rate surge may be useful for predicting which patients with OSA are at increased risk for incident AF.